COVID-19 IMMUNOLOGIC PLANT-BASED MANUFACTURING
Financed · Mauritius
Source: European Investment Bank (EIB)
The project aims to establish a new plant-based cGMP-level manufacturing facility together with related processing laboratories and climate controlled hydroponic grow rooms to produce reagents for testing and treatment of COVID 19 and other endemic African diseases (e.g. Ebola, Dengue, Measles, HIV or yellow fever) in Mauritius. The facility is expected to reach a production capacity equivalent t
- Status
- Prospective
- Sector
- Manufacturing (Industrial), Government
- Location
- Mauritius
- Updated
- 19 Nov 2026
- Source
- European Investment Bank (EIB)
ConstructChat
Ask ConstructChat about COVID-19 IMMUNOLOGIC PLANT-BASED MANUFACTURING
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | financed |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | The project aims to establish a new plant-based cGMP-level manufacturing facility together with related processing laboratories and climate controlled hydroponic grow rooms to produce reagents for testing and treatment of COVID 19 and other endemic African diseases (e.g. Ebola, Dengue, Measles, HIV or yellow fever) in Mauritius. The facility is expected to reach a production capacity equivalent to 100 million test kits and/or vaccines per month. |
Original sector | Industry |
Budget |
Location
Country | Mauritius |
Source
Source reliability | High |
Source | European Investment Bank (EIB) |
URL |
More Details
Record type | Project |
Sector | Manufacturing (Industrial), Government |
Article published date | 2023-05-08 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
